| ￥3300 | |
| Z05810-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 98.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 145-150 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized SEZ6, His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SEZ6 Antibody, hFc Tag with the EC50 of 4.5ng/ml determined by ELISA. »
The purity of SEZ6, His, Human is greater than 90% as determined by SEC-HPLC. »
SEZ6, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Seizure-related protein 6 (Sez6) contributes to chronic pain development as sez6 knockout mice show attenuated pain behaviours after peripheral nerve injury, compared with control mice. The type I transmembrane isoform of Sez6 is cleaved by the β-amyloid precursor protein cleavage enzyme 1 (BACE1), resulting in Sez6 extracellular domain shedding from the neuron surface. |
| Synonyms | SEZ-6; SEZ6; BSRPC; BSRP-C |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
